Director James Healy buys $20.4 million of Rapport Therapeutics, Inc. (RAPP)

James Healy, director of Rapport Therapeutics, Inc., bought 969,480 shares on the open market on October 28, 2026 at an average of $21.00 a share, for a total of $20.4 million. The purchase was reported to the SEC on Form 4 on October 30, 2026.

It is a new position: the filing shows no shares held directly before this purchase.

6 other insiders also bought at least $10,000 of RAPP within 30 days, which makes this a cluster buy.

In the 12 months up to this filing, Rapport Therapeutics, Inc. insiders reported 7 open-market purchases and 32 sales.

WallStPal Score: 62 out of 100, because of a brand-new position; a large purchase; 6 other insiders also bought.

It is too soon to say how the stock did afterward. This page will update as prices come in.

Our read

This one purchase is 92% of all insider buying at RAPP in the past year, the first open-market purchase by James Healy in our records. It is worth reading next to the company's own results and news before drawing conclusions.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.

Explain it like I'm 13

James Healy helps run Rapport Therapeutics, Inc.. Spending $20.4 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all RAPP insider trades · James Healy's track record